TriangleDISEASE & TREATMENT SETTING
Renal Cell Cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Renal Cell Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- unresolved
- derivation note
- Derived from NCI topic(s): Renal Cell Cancer. Strongest NCIt resolution: ambiguous. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
32 more-specific settings
Sutent: advanced Renal cell carcinoma →PROLEUKIN: metastatic Renal cell carcinoma →SUTENT: recurrent Renal cell carcinoma (adjuvant) after prior therapy →OPDIVO: advanced Renal cell carcinoma after prior therapy →INLYTA: advanced Renal cell carcinoma (second-line) after prior therapy →Torisel: advanced Renal cell carcinoma →Vegzelma: metastatic Renal cell carcinoma →CABOMETYX: advanced Renal cell carcinoma →Lenvima: advanced Renal cell carcinoma (first-line) →FOTIVDA: refractory Renal cell carcinoma after prior therapy →Nexavar: advanced Renal cell carcinoma →BAVENCIO: advanced Renal cell carcinoma (first-line) →Afinitor: advanced Renal cell carcinoma after prior therapy →INLYTA: advanced Renal cell carcinoma (first-line) →VOTRIENT: advanced Renal cell carcinoma →INLYTA: advanced Renal cell carcinoma after prior therapy →YERVOY: advanced Renal cell carcinoma (first-line) →Zirabev: metastatic Renal cell carcinoma →Avastin: metastatic Renal cell carcinoma →WELIREG: metastatic Renal cell carcinoma (adjuvant) after prior therapy →OPDIVO QVANTIG: advanced Renal cell carcinoma (first-line) after prior therapy →KEYTRUDA QLEX: advanced Renal cell carcinoma (first-line) →KEYTRUDA: advanced Renal cell carcinoma (first-line) →MVASI: metastatic Renal cell carcinoma →Lenvima: advanced Renal cell carcinoma after prior therapy →ALYMSYS: metastatic Renal cell carcinoma →JOBEVNE: metastatic Renal cell carcinoma →Stage I Renal Cell Cancer →Stage II Renal Cell Cancer →Stage III Renal Cell Cancer →Stage IV recurrent Renal Cell Cancer →Stage IV Renal Cell Cancer →
Study evidence for this setting
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Suniti
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and R
Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth
Cancer in Patients With Gabapentin (GPRD)
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Molecular-Guided Therapy for Childhood Cancer
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Indication-specific source history
2006-01-26 · Sutent (sunitinib maleate) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-renal-cell-cancer
- event id
- fda-2f9ae05a6557dfe9
- event date
- 2006-01-26
- event kind
- accelerated-approval
- drug or regimen
- Sutent (sunitinib maleate)
- source indication text
- Advanced renal cell carcinoma
- match phrase
- renal cell carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-28094d104239a2e46d16
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2007-02-02 · Sutent (sunitinib maleate) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-renal-cell-cancer
- event id
- fda-81fe0d67adecd915
- event date
- 2007-02-02
- event kind
- traditional-approval
- drug or regimen
- Sutent (sunitinib maleate)
- source indication text
- Advanced renal cell carcinoma
- match phrase
- renal cell carcinoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-28094d104239a2e46d16
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-06-12 · belzutifan with pembrolizumab · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-renal-cell-cancer
- event id
- notice-ec77532f04080584
- event date
- 2026-06-12
- event kind
- approval-notification
- drug or regimen
- belzutifan with pembrolizumab
- source indication text
- FDA approved belzutifan in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
- match phrase
- renal cell carcinoma
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-69399853a62eefe0
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-renal-cell-cancer
- binding id
- ncit-C6568
- source collection
- ncit-concept
- source key
- C6568
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-renal-cell-cancer
- binding id
- ncit-C9385
- source collection
- ncit-concept
- source key
- C9385
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice